Regional Differences in the Phase III Meteor Study of Cabozantinib (CABO) Versus Everolimus (EVE) in Advanced Renal Cell Carcinoma (RCC)

被引：0
|
作者：
Mainwaring, Paul [1 ]
Tannir, Nizar M. [1 ]
Powles, Thomas [1 ]
Motzer, Robert J. [1 ]
Rolland, Frederic [1 ]
Gravis, Gwanaelle [1 ]
Staehler, Michael [1 ]
Rink, Michael [1 ]
Retz, Margitta [1 ]
Csoszi, Tibor [1 ]
McCaffrey, John A. [1 ]
De Giorgi, Ugo [1 ]
Caserta, Claudia [1 ]
Cheporov, Sergey [1 ]
Gonzalez, Emilio Esteban [1 ]
Duran, Ignacio [1 ]
Larkin, James G. [1 ]
Berg, William [1 ]
Clary, Douglas O. [1 ]
Escudier, Bernard [1 ]
Choueiri, Toni K. [1 ]
机构：
[1] Mater Med Ctr, ICON Canc Care, South Brisbane, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
183
引用
收藏
页码：129 / 130
页数：2
相关论文
共 50 条
  • [31] Phase 3 randomized study of cabozantinib (XL184) versus everolimus in subjects with dear cell renal cell carcinoma (METEOR)
    Choueiri, Toni K.
    Escudier, Bernard J.
    Les, Thomas Pow
    Cella, David
    Ru, Qinhua C.
    Scheffold, Christian
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
    Choueiri, Toni K.
    Escudier, Bernard
    Powles, Thomas
    Tannir, Nizar M.
    Mainwaring, Paul N.
    Rini, Brian I.
    Hammers, Hans J.
    Donskov, Frede
    Roth, Bruce J.
    Peltola, Katriina
    Lee, Jae Lyun
    Heng, Daniel Y. C.
    Schmidinger, Manuela
    Agarwal, Neeraj
    Sternberg, Cora N.
    McDermott, David F.
    Aftab, Dana T.
    Hessel, Colin
    Old, Christian Scheff
    Schwab, Gisela
    Hutson, Thomas E.
    Pal, Sumanta
    Motzer, Robert J.
    LANCET ONCOLOGY, 2016, 17 (07): : 917 - 927
  • [33] Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR)
    Schmidinger, M.
    Motzer, R. J.
    Powles, T.
    Escudier, B.
    Tannir, N. M.
    Mainwaring, P. N.
    Rini, B. I.
    Hammers, H. J.
    Donscov, F.
    Roth, B.
    Peltola, K.
    Lee, J. L.
    Heng, D. Y. C.
    Aftab, D. T.
    Hessel, C.
    Scheffold, C.
    Schwab, G.
    Pal, S.
    Hutson, T. E.
    Choueiri, T. K.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S187 - S188
  • [34] CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).
    Motzer, Robert J.
    Sharma, Padmanee
    McDermott, David F.
    George, Saby
    Hammers, Hans J.
    Srinivas, Sandhya
    Tykodi, Scott S.
    Sosman, Jeffrey Alan
    Procopio, Giuseppe
    Plimack, Elizabeth R.
    Castellano, Daniel E.
    Gurney, Howard
    Donskov, Frede
    Bono, Petri
    Wagstaff, John
    Gauler, Thomas Christoph
    Ueda, Takeshi
    Zhao, Huanyu
    Waxman, Ian M.
    Escudier, Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [35] Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial
    Denize, Thomas
    Farah, Subrina
    Cimadamore, Alessia
    Flaifel, Abdallah
    Walton, Emily
    Sticco-Ivins, Maura A.
    Labaki, Chris
    Braun, David A.
    Sun, Maxine
    Wang, Evelyn
    Xie, Wanling
    Choueiri, Toni K.
    Signoretti, Sabina
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 748 - 755
  • [36] Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
    Powles, Thomas
    Choueiri, Toni K.
    Motzer, Robert J.
    Jonasch, Eric
    Pal, Sumanta
    Tannir, Nizar M.
    Signoretti, Sabina
    Kaldate, Rajesh
    Scheffold, Christian
    Wang, Evelyn
    Aftab, Dana T.
    Escudier, Bernard
    George, Daniel J.
    BMC CANCER, 2021, 21 (01)
  • [37] Phase 2 trial for sequential treatment of high dose cabozantinib (CABO) or CABO plus nivolumab (NIVO) on/after progression on CABO monotherapy in advanced renal cell carcinoma (RCC): Seq-Cabo
    Qin, Qian
    Brugarolas, James
    Hammers, Hans J.
    Arafat, Waddah
    Courtney, Kevin Dale
    Wang, Jue
    Jiang, Changchuan
    Zhang, Song
    Cowey, Charles Lance
    Hutson, Thomas E.
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study
    Schmidinger, Manuela
    Motzer, Robert J.
    Rolland, Frederic
    Straehler, Michael
    Rink, Michael
    Retz, Margitta
    Csoszi, Tibor
    McCaffrey, John A.
    De Giorgi, Ugo
    Caserta, Claudia
    Duran, Ignacio
    Benzaghou, Fawzi
    Clary, Douglas O.
    Albiges, Laurence
    Choueiri, Toni K.
    Tannir, Nizar M.
    ACTA ONCOLOGICA, 2022, 61 (01) : 52 - 57
  • [39] Effect of prior systemic therapy on clinical outcomes with cabozantinib vs everolimus in advanced renal cell carcinoma: Results from the phase 3 METEOR study
    Grande, E.
    Choueiri, T. K.
    Motzer, R. J.
    Escudier, B.
    Pal, S.
    Kollmannsberger, C.
    Pikiel, J.
    Gurney, H.
    Rha, S. Y.
    Park, S. H.
    Geertsen, P. F.
    Goupil, M. Gross
    Suarez, C.
    Arroyo, A.
    Dean, M.
    George, D.
    Powles, T.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S197 - S198
  • [40] Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
    Thomas Powles
    Toni K. Choueiri
    Robert J. Motzer
    Eric Jonasch
    Sumanta Pal
    Nizar M. Tannir
    Sabina Signoretti
    Rajesh Kaldate
    Christian Scheffold
    Evelyn Wang
    Dana T. Aftab
    Bernard Escudier
    Daniel J. George
    BMC Cancer, 21
12345